WuXi XDC out-licenses WuXiTecan-2 payload-linker platform to Ona Therapeutics
WuXi XDC said it has out-licensed its WuXiTecan-2 payload-linker technology platform to Ona Therapeutics to support novel ADC research and development.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.